SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Decnupaz

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and on the market, FDA original approval granted 2026-05-27 (BLA 761460).
Why 3/10
No dated binary is scheduled for Decnupaz in the next ~12 months, the defining catalyst (FDA approval) already passed on 2026-05-27, and as an approved niche orphan-drug launch inside a mega-cap pipeline with no pending PDUFA/readout, near-term share-price impact is small.
Actionable Insight NEUTRAL

Watch AbbVie earnings calls for first commercial-update commentary on Decnupaz (launch ramp, pricing, and any label-expansion trial starts), but treat this as a rounding-error program for a ~$250B company rather than a stock-driving catalyst.

Price Chart

Loading chart...

Executive Summary

Decnupaz (generic: pivekimab sunirine) is AbbVie's intravenously administered, new-molecular-entity cancer drug that the FDA approved on 2026-05-27 under priority review with orphan-drug designation (BLA 761460, AbbVie Inc. as sponsor). The approval is a genuine regulatory win but sits inside AbbVie's enormous diversified portfolio, so it is immaterial to the stock's valuation.

How It Works

Decnupaz is an intravenously infused prescription cancer medicine, a brand-new molecular entity (Type 1 NME) approved with orphan-drug (rare-disease) status.

Trial Status

FDA granted an original approval (Type 1 New Molecular Entity) on 2026-05-27 under PRIORITY review with orphan-drug designation, per the FDA action record (application BLA761460, sponsor AbbVie Inc.). The record shows a prescription, single-dose 2 mg intravenous vial; no pending regulatory decision or next readout was identified in local data.

The Two-Sided Case

▲ Bull Case4
FDA approved Decnupaz (pivekimab sunirine-pvzy) on 2026-05-27 as a Type 1 New Molecular Entity under priority review with orphan-drug designation (BLA 761460), an unambiguous regulatory success for AbbVie.
Orphan designation gives Decnupaz a rare-disease niche with potential orphan exclusivity and premium pricing dynamics typical of such drugs, inside a company with deep commercial infrastructure.
ABBV carries no Decnupaz-specific overhang: analyst consensus is 'buy' (22 buy + 9 strong buy, 0 sell; mean price target $270.39, ~11.6% implied upside vs. the $250.94 quote), and the stock trades near its 52-week high of $267.47.
AbbVie is one of the largest US pharma names, so launch execution risk is low and balance-sheet support is not a concern.
▼ Bear Case3
No upcoming hard catalyst: the approval binary already passed, and no PDUFA, pivotal readout, or advisory-committee date for Decnupaz appears in local FDA/catalyst data, nothing scheduled to move the stock on this name within ~12 months.
Concentration is extreme in the wrong direction for this drug: at ~$250B market cap, one niche orphan oncology launch is a rounding error; even a strong launch is unlikely to move ABBV.
Company-level regulatory risk exists regardless: FDA issued a Complete Response Letter to AbbVie for trenibotulinumtoxinE on 2026-04-29 (SEC-extracted catalyst record), a reminder that AbbVie's regulatory calendar is not risk-free.

Upcoming Catalysts

  • None confirmed for Decnupaz: no pending PDUFA, advisory-committee, or pivotal-readout date identified in local data.
  • First commercial/launch commentary on Decnupaz in AbbVie quarterly earnings (next 10-Q/earnings call), watch for revenue disclosure and label-expansion trial starts.
  • Any future sNDA filing for additional indications would be the next potential hard catalyst, but none is scheduled per available data.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 6

Hover a chip for the title
1 accessdata.fda.gov2 accessdata.fda.gov3 accessdata.fda.gov4 sec.gov5 sec.gov6 sec.gov